Compare PLAB & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAB | NTLA |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 1995 | 2016 |
| Metric | PLAB | NTLA |
|---|---|---|
| Price | $48.07 | $13.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 21 |
| Target Price | ★ $44.33 | $20.23 |
| AVG Volume (30 Days) | 803.7K | ★ 3.9M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.09 | ★ 27.43 |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $535,276,000.00 | $67,671,000.00 |
| Revenue This Year | $6.70 | N/A |
| Revenue Next Year | $4.96 | $62.75 |
| P/E Ratio | $69.43 | ★ N/A |
| Revenue Growth | ★ 18.77 | 16.92 |
| 52 Week Low | $16.59 | $6.83 |
| 52 Week High | $52.79 | $28.24 |
| Indicator | PLAB | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 46.16 |
| Support Level | $21.30 | $11.93 |
| Resistance Level | N/A | $14.32 |
| Average True Range (ATR) | 2.05 | 1.11 |
| MACD | 0.17 | -0.16 |
| Stochastic Oscillator | 49.74 | 22.25 |
Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.